These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31006013)

  • 1. Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.
    Lamina C; Kronenberg F; Stenvinkel P; Froissart M; Forer L; Schönherr S; Wheeler DC; Eckardt KU; Floege J
    Nephrol Dial Transplant; 2020 Mar; 35(3):478-487. PubMed ID: 31006013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.
    Floege J; Kim J; Ireland E; Chazot C; Drueke T; de Francisco A; Kronenberg F; Marcelli D; Passlick-Deetjen J; Schernthaner G; Fouqueray B; Wheeler DC;
    Nephrol Dial Transplant; 2011 Jun; 26(6):1948-55. PubMed ID: 20466670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines.
    Liu Y; Lee WC; Cheng BC; Li LC; Lee CH; Chang WX; Chen JB
    Biomed Res Int; 2016; 2016():1523124. PubMed ID: 28003998
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study.
    Fernández-Martín JL; Dusso A; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Górriz JL; Rutkowski B; Bos WJ; Tielemans C; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Rodríguez-Puyol D; Carrero JJ; Zoccali C; Cannata-Andía JB;
    Nephrol Dial Transplant; 2019 Apr; 34(4):673-681. PubMed ID: 29741651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes.
    Stevens LA; Djurdjev O; Cardew S; Cameron EC; Levin A
    J Am Soc Nephrol; 2004 Mar; 15(3):770-9. PubMed ID: 14978180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
    Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M
    Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.
    Wang M; Obi Y; Streja E; Rhee CM; Lau WL; Chen J; Hao C; Hamano T; Kovesdy CP; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1118-1127. PubMed ID: 28487345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relation Between Variability of Intact Parathyroid Hormone, Calcium, and Cardiac Mortality in Hemodialysis Patients.
    Ulusoy S; Ozkan G; Guvercin B; Yavuz A
    Artif Organs; 2016 Nov; 40(11):1078-1085. PubMed ID: 27110947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N; Wagner M; Griffith JL; Miskulin DC; Hodsman A; Ansell D; Naimark DM
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.
    Soohoo M; Feng M; Obi Y; Streja E; Rhee CM; Lau WL; Wang J; Ravel VA; Brunelli S; Kovesdy CP; Kalantar-Zadeh K
    Am J Nephrol; 2016; 43(2):85-96. PubMed ID: 26950688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
    Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
    Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study.
    Molina P; Molina MD; Pallardó LM; Torralba J; Escudero V; Álvarez L; Peris A; Sánchez-Pérez P; González-Rico M; Puchades MJ; Fernández-Nájera JE; Giménez-Civera E; D'Marco L; Carrero JJ; Górriz JL
    J Nephrol; 2021 Aug; 34(4):1189-1199. PubMed ID: 33394344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study.
    Asada S; Yokoyama K; Miyakoshi C; Fukuma S; Endo Y; Wada M; Nomura T; Onishi Y; Fukagawa M; Fukuhara S; Akizawa T
    Clin Exp Nephrol; 2020 Jul; 24(7):630-637. PubMed ID: 32236781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?
    Fouque D; Roth H; Pelletier S; London GM; Hannedouche T; Jean G; Bouchet JL; Drüeke T
    Nephrol Dial Transplant; 2013 Feb; 28(2):360-7. PubMed ID: 23136211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical markers of mineral bone disorder in South African patients on maintenance haemodialysis.
    Waziri B; Duarte R; Naicker S
    Afr Health Sci; 2017 Jun; 17(2):445-452. PubMed ID: 29062340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.
    Chiroli S; Mattin C; Belozeroff V; Perrault L; Mitchell D; Gioni I
    BMC Nephrol; 2012 Oct; 13():140. PubMed ID: 23106934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of CKD-MBD Markers with All-Cause Mortality in Prevalent Hemodialysis Patients: A Cohort Study in Beijing.
    Li D; Zhang L; Zuo L; Jin CG; Li WG; Chen JB
    PLoS One; 2017; 12(1):e0168537. PubMed ID: 28045985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients.
    Zhou X; Guo Y; Luo Y
    Ren Fail; 2021 Dec; 43(1):599-605. PubMed ID: 33781171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.